Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CERo Therapeutics Holdings, Inc. (CERO : OTC)

• Company Description    CERo Therapeutics Holdings Inc. is an immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. The company's lead product candidate includes CER-1236. CERo Therapeutics Holdings Inc., formerly known as Phoenix Biotech Acquisition Corp., is based in OAKLAND, Calif. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $0.12 Daily Weekly Monthly 20 Day Moving Average: 7,341,546 shares Shares Outstanding: 1.21 (millions) Market Capitalization: $0.14 (millions) Beta: 0.30 52 Week High: $94.60 52 Week Low: $0.06 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -96.38% -96.47% 12 Week -98.50% -98.56% Year To Date -99.90% -99.91%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201 Haskins Way Suite 230 - South San Francisco,CA 94080 USA ph: 650-407-2376 fax: - investors@cero.bio http://www.cero.bio

• General Corporate Information    Officers Chris Ehrlich - Chairman and Chief Executive Officer and Director Andrew Kucharchuk - Chief Financial Officer Brian Atwood - Director Michael Byrnes - Director Shami Patel - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 71902K402 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/18/25 Share - Related Items Shares Outstanding: 1.21 Most Recent Split Date: 6.00 (0.05:1) Beta: 0.30 Market Capitalization: $0.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/18/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 90.65% vs. Previous Quarter: -94.06% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - -209.40 03/31/25 - -199.71 Current Ratio 09/30/25 - - 06/30/25 - 0.56 03/31/25 - 0.73 Quick Ratio 09/30/25 - - 06/30/25 - 0.56 03/31/25 - 0.73 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - -26.44 03/31/25 - -10.25 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©